GenFleet Therapeutics

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included

Innovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and

The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including risi

Amid the global race to scour for the best partners and approaches for KRAS G12C inhibitors for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the hard-to-drug mutat